Complete Guide to Docetaxel Pharmacokinetics

Overview

Docetaxel is a Taxane / Microtubule stabilizer used in the Oncology therapeutic area. It is indicated for Breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head and neck cancer. Interactive docetaxel population PK simulator based on the Bruno et al. model. Docetaxel is a taxane chemotherapeutic that stabilizes beta-tubulin microtubules, blocks mitosis, and drives tumor cell death. The simulator supports IV dosing, exposure prediction, and covariate effects relevant to major solid tumors including breast, lung, prostate, gastric, and head and neck cancers.

Mechanism of Action

Docetaxel exerts its pharmacological effect by targeting Beta-tubulin microtubules. As a Taxane / Microtubule stabilizer, it modulates this target to achieve therapeutic efficacy in Breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head and neck cancer. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.

Key Pharmacokinetic Parameters

This 3-compartment PopPK with covariate effects model for Docetaxel characterizes the time-course of drug concentrations following IV infusion administration. Key parameters such as clearance (CL), volume of distribution (Vd), and absorption rate constant (Ka) define the drug's disposition. Use the interactive simulator below to explore these parameters in detail.

Dosing & Administration

Docetaxel is administered via the IV infusion route. Intravenous administration provides 100% bioavailability and allows precise control of drug exposure. Infusion duration and rate can significantly impact peak concentrations.

Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, C_max, and C_trough.

Clinical Considerations

In the Oncology therapeutic area, for the treatment of Breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head and neck cancer, understanding the pharmacokinetics of Docetaxel is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Docetaxel pharmacokinetics include:

• •Body weight and body composition
• •Renal and hepatic function
• •Drug-drug interactions and concomitant medications
• •Age, sex, and genetic polymorphisms

Frequently Asked Questions